The Method of Analyzing Antigen-Specific Polyfunctional T Lymphocytes

By measuring antigen-specific multifunctional T lymphocytes using CyTOF, the method addresses the limitations of humoral immune response assessments, providing a more accurate evaluation of cellular immunity and vaccine efficacy.

KR103046227B1Active Publication Date: 2026-11-11KOREA UNIV RES & BUSINESS FOUND
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
KR1020230172315
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2022-12-02
Filing Date
2023-12-01
Publication Date
2026-11-11
Estimated Expiration
2043-12-01

AI Technical Summary

Technical Problem

Current methods primarily rely on measuring humoral immune responses, such as neutralizing antibodies, to assess vaccine efficacy and infection history, which may not accurately reflect cellular immunity against pathogens like viruses or cancer cells.

Method used

A method is developed to measure cellular immune responses using antigen-specific multifunctional T lymphocytes, specifically detecting these cells in a sample stimulated by an antigen, utilizing techniques like CyTOF to analyze cytokine and chemokine secretion.

Benefits of technology

This approach allows for more accurate determination of acquired immunity by evaluating the functional capabilities of T lymphocytes, enabling better assessment of vaccine efficacy and infection history.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112023134871317-PAT00002_ABST
    Figure 112023134871317-PAT00002_ABST
Patent Text Reader

Abstract

The antigen-specific multifunctional T lymphocyte analysis method according to the present invention relates to a method for measuring the cellular immune response to a specific antigen using antigen-specific multifunctional T lymphocytes, or a method for providing information to confirm whether acquired immunity to a specific antigen has been acquired. Since it allows for more accurate confirmation of whether acquired immunity to a specific antigen has been acquired, it can be effectively utilized in the treatment of diseases, including infectious diseases, and in the development of pharmaceuticals, as well as being usable as a material for pharmaceuticals.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to a method for analyzing antigen-specific multifunctional T lymphocytes, and specifically, to a method for measuring a cellular immune response to a specific antigen using antigen-specific multifunctional T lymphocytes, or a method for providing information to confirm whether acquired immunity to a specific antigen has been acquired. Background Technology

[0003] The human immune system is divided into innate immunity and adaptive immunity. Adaptive immunity is further divided into humoral immunity, mediated by B lymphocytes, and cellular immunity, mediated by T lymphocytes. Adaptive immunity is an immune system that acts against external pathogens that have already been experienced and remembered; compared to innate immunity, it is known to react to external pathogens more rapidly, strongly, and accurately, thereby eliminating them from the body more efficiently. Furthermore, within adaptive immunity, cellular immunity mediated by T lymphocytes refers to antigen-specific immunity caused by T lymphocytes, meaning that T lymphocytes directly participate in the immune response.

[0004] Currently, it is known that the acquisition of immunity against pathogenic infectious agents such as viruses or cancer cells is primarily determined by measuring humoral immune responses, such as the ability to form neutralizing antibodies or the amount of neutralizing antibodies.

[0005] However, concerns have been raised that neutralizing antibodies may not play a significant role in evaluating vaccine efficacy against viral variants. Furthermore, to accurately measure vaccination against specific antigens or infection history, it is preferable to assess the acquisition of adaptive immunity by measuring cellular immunity mediated by T lymphocytes specific to the infectious agent, rather than humoral immunity related to antibodies; yet, research in this area is currently lacking. Prior art literature

[0007] Republic of Korea Registered Patent No. 10-2405649 The problem to be solved

[0008] The object of the present invention is to provide a method for measuring a cellular immune response to a specific antigen using T lymphocytes, comprising the step of detecting antigen-specific multifunctional T lymphocytes in a sample stimulated by an antigen.

[0009] Another objective of the present invention is to provide a method for providing information for determining whether acquired immunity to a specific antigen has been acquired, comprising the step of detecting antigen-specific multifunctional T lymphocytes in a sample stimulated by the antigen. means of solving the problem

[0011] This is explained in detail as follows. Meanwhile, each description and embodiment disclosed in this application may be applied to each other description and embodiment. That is, all combinations of the various elements disclosed in this application fall within the scope of this application. Furthermore, the scope of this application should not be considered limited by the specific descriptions provided below.

[0012] As one embodiment for achieving the above objective, the present invention provides a method for measuring a cellular immune response to a specific antigen using T lymphocytes, comprising the step of detecting antigen-specific multifunctional T lymphocytes in a sample stimulated by an antigen.

[0013] In the present invention, the method for measuring the cellular immune response of a specific antigen may be to obtain a sample stimulated by the antigen by contacting an antigen-derived peptide with a separated sample and culturing it.

[0014] In the present invention, the method for measuring the cellular immune response to a specific antigen may involve detecting antigen-specific multifunctional T lymphocytes in a sample to confirm whether immunity to the antigen has been acquired.

[0015] In the present invention, the antigen-specific multifunctional T lymphocyte may be a memory T lymphocyte, preferably a late memory T lymphocyte, but is not limited thereto.

[0016] In the present invention, the term 'T lymphocyte' refers to one of the lymphocytes responsible for adaptive immunity specific to a specific antigen, which matures in the thymus. T lymphocytes are classified according to their function into non-contact T lymphocytes, effector T lymphocytes, and memory T lymphocytes. Memory T lymphocytes are further classified into early, mid, and late T lymphocytes according to the differentiation stage, and each expresses various cytokines, chemokines, and / or cell surface markers depending on the differentiation stage or external / internal stimuli.

[0017] In the present invention, antigen-specific multifunctional T lymphocytes mean that they secrete two or more cytokines, but are not limited thereto.

[0018] In the present invention, the term 'antigen-specific multifunctional T lymphocyte' refers to a T lymphocyte that has the ability to specifically react to a specific antigen and perform various functions, and which secretes various cytokines, chemokines, cell surface markers, or cytotoxic granules.

[0019] In the present invention, the term 'cytokine' refers to a type of protein secreted by a cell that plays an important role in cell signaling and is secreted by an immune cell. Cytokines are secreted from cells and can affect other cells or the secreting cell itself, and their types include interleukin (IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, etc.), CSF (GM-CSF, G-CSF, etc.), tumor necrosis factor (TNFα, β), interferon (IFNα, β, γ), MIP1a (Macrophage inflammatory protein 1a), or MIP1b.

[0020] In the present invention, the term 'chemokine' refers to a highly conserved small cytokine secreted by leukocytes as well as other cells that induce directional movement, and types include CCL2, CCL1, CCL22, or CCL17.

[0021] In the present invention, the term 'cell surface marker' refers to a special protein or sugar expressed on the cell surface, which is often used as a marker for a specific cell type, and includes CD3, CD4, CD8, CD25, CD27, CD45RA, or CD45RO.

[0022] In the present invention, antigen-specific multifunctional T lymphocytes mean that they secrete two or more cytokines, but are not limited thereto.

[0023] In the present invention, antigen-specific pluripotent T lymphocytes may secrete two or more cytokines such as interleukin (IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, etc.), CSF (GM-CSF, G-CSF, etc.), tumor necrosis factor (TNFα, β), interferon (IFNα, β, γ), MIP1a, or MIP1b, and preferably may secrete two or more cytokines selected from the group consisting of IL-2, IFNγ, TNFα, and MIP1b, but are not limited thereto.

[0024] In the present invention, the sample may be blood, tears, sweat, saliva, nasopharyngeal fluid, urine, or feces of a person or animal, or may be separated from blood, tears, sweat, urine, or feces of a person or animal, and specifically may be separated from human blood, but is not limited thereto.

[0025] In the present invention, the sample may be a cell, specifically a peripheral blood mononuclear cell (PBMC), but is not limited thereto.

[0026] In the present invention, the antigen may be an environmental allergen such as bacteria, viruses, fungi, cancer cells, food, or pollen, an autoantigen, or an antigen derived from a vaccine, and preferably may be a virus, but is not limited thereto.

[0027] In the present invention, the virus may be an adenovirus, coronavirus, norovirus, Epstein-Barr virus, retrovirus, or herpesvirus, preferably a coronavirus, and more preferably SARS-CoV2, but is not limited thereto.

[0028] In the present invention, the term 'coronavirus' refers to the Coronavirus family ( Coronaviridae ) Coronavirus subfamily ( Coronavirinae It is a general term for RNA viruses belonging to the group that cause respiratory and digestive system infections in animals, including humans, and is known to be the cause of a significant portion of the common cold in humans. In particular, several variants of human coronavirus are known, specifically SARS-CoV, SARS-CoV2, HCoV-229E, HCoV-OC43, HCoV-NL63, MERS-CoV, etc.

[0029] In the present invention, the term 'SARS-CoV2 (Severe acute respiratory syndrome coronavirus 2)' refers to a type of coronavirus that has strong genetic similarity to the Bat SARS-like coronavirus and appears to have originated from it, and is known as the cause of the COVID-19 outbreak that started in Wuhan, China in 2019 and led to an international public health emergency.

[0030] In the present invention, the term "autoantigen" refers to a tissue component that exhibits immunogenicity within one's own body and stimulates the production of autoantibodies within one's own tissue.

[0031] In the present invention, the step of measuring the antigen-specific multifunctional T lymphocytes may be performed using CytoF (Cytometry by time of flight) or a flow cytometer, and preferably using CytoF, but is not limited thereto.

[0032] In the present invention, when detecting antigen-specific multifunctional T lymphocytes using CyTOF, there is an advantage in that immunological expression can be measured at a lower frequency than when using a flow cytometer.

[0033] In the present invention, the term 'flow cytometry' refers to a technology used in protein engineering that counts or classifies cells and detects biomarkers by stopping or sending fluidly flowing cells using a laser-based electrical detection technology.

[0034] In the present invention, the term 'mass cytometry' refers to a technology that determines cell characteristics by counting cells or detecting biomarkers by analyzing the mass of rare elements labeled on antibodies, and CyTOF is a representative example. CyTOF is an application device of mass cytometry used to quantify targets labeled on the surface and inside a single cell, and CyTOF can quantify multiple cellular components simultaneously.

[0035] According to the method for confirming whether acquired immunity to a specific antigen has been acquired according to the present invention, whether immunity to a specific antigen has been acquired can be measured more accurately than a measurement method through the formation of neutralizing antibodies.

[0036] In the present invention, the term 'acquired immunity' refers to immunity obtained by already contracting a disease through infection with viruses, pathogens, etc., or by generating cancer cells, etc., or by vaccination, and is known to react to external pathogens more quickly, strongly, and accurately than innate immunity, thereby enabling more efficient removal of pathogens from the body.

[0037] In the present invention, the term 'immunity acquisition' may be acquired through contact with bacteria, viruses, fungi, cancer cells, food, pollen, autoantigens, or antigens contained in vaccines, but is not limited thereto.

[0038] In the present invention, the term "comprising" is intended to specify the existence of the steps, components, actions, numbers, or combinations thereof described in the specification, and should be understood as not excluding in advance the existence or addition of one or more other steps, components, actions, numbers, or combinations thereof.

[0039] In another embodiment for achieving the above objective, the present invention provides a method for providing information for confirming whether acquired immunity to a specific antigen has been acquired, comprising the step of detecting antigen-specific multifunctional T lymphocytes in a sample stimulated by an antigen.

[0040] In the present invention, a method for providing information to confirm whether acquired immunity to a specific antigen has been acquired may be to obtain a sample stimulated by an antigen by contacting an antigen-derived peptide with a separated sample and culturing it.

[0041] In the present invention, a method for providing information to confirm whether acquired immunity to a specific antigen has been acquired may be to confirm whether immunity to the antigen has been acquired by detecting antigen-specific multifunctional T lymphocytes in a sample.

[0042] In the present invention, antigen-specific pluripotent T lymphocytes may secrete two or more cytokines such as interleukin (IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, etc.), CSF (GM-CSF, G-CSF, etc.), tumor necrosis factor (TNFα, β), interferon (IFNα, β, γ), MIP1a, or MIP1b, and preferably may secrete two or more cytokines selected from the group consisting of IL-2, IFNγ, TNFα, and MIP1b, but are not limited thereto.

[0043] In the present invention, the sample may be blood, tears, sweat, saliva, nasopharyngeal fluid, urine, or feces of a person or animal, or may be separated from blood, tears, sweat, urine, or feces of a person or animal, and specifically may be separated from human blood, but is not limited thereto.

[0044] In the present invention, the sample may be a cell, specifically a peripheral blood mononuclear cell, but is not limited thereto.

[0045] In the present invention, the antigen may be an environmental allergen such as bacteria, viruses, fungi, cancer cells, food, or pollen, an autoantigen, or an antigen derived from a vaccine, and preferably may be a virus, but is not limited thereto.

[0046] In the present invention, the virus may be an adenovirus, coronavirus, norovirus, Epstein-Barr virus, retrovirus, or herpesvirus, preferably a coronavirus, and more preferably SARS-CoV2, but is not limited thereto.

[0047] In the present invention, the step of detecting antigen-specific multifunctional T lymphocytes may be measured using a CyTOF or a flow cytometer, and preferably may use a CyTOF, but is not limited thereto.

[0048] In the present invention, when detecting antigen-specific multifunctional T lymphocytes using CyTOF, there is an advantage in that immunological expression can be measured at a lower frequency than when using a flow cytometer.

[0049] The above 'antigen', 'antigen-specific pluripotent T lymphocyte', 'cytokine', 'chemokine', 'cell surface marker', 'sample', 'antigen', 'virus', 'flow cytometry', 'mass cytometry', 'acquired immunity', 'immunity acquisition', 'coronavirus', and 'comprising' are as described above.

[0050] The present invention will be described in more detail below through examples. These examples are solely for illustrating the present invention, and it will be obvious to those skilled in the art that the scope of the present invention is not to be interpreted as being limited by these examples. Effects of the invention

[0052] A method for determining whether acquired immunity to a specific antigen has been acquired, comprising the steps of contacting a sample with an antigen according to the present invention and analyzing antigen-specific multifunctional T lymphocytes contained in the sample contacted with the antigen. Since the acquisition of acquired immunity to a specific antigen can be determined more accurately, it can be effectively utilized in the treatment of diseases, including infectious diseases, and in the development of pharmaceuticals, as well as utilized as a material for pharmaceuticals. Brief explanation of the drawing

[0054] FIG. 1 is a schematic diagram illustrating a method for analyzing antigen-specific multifunctional T lymphocytes according to the present invention. Figure 2 shows the results of analyzing the expression of CD45RO, CD27, IL-2, IFNγ, TNFα, and MIP1b in antigen-specific pluripotent T lymphocytes using CyTOF. Specific details for implementing the invention

[0055] The present invention will be explained in more detail below through the following examples. However, these examples are intended to illustrate the invention and the scope of the invention is not limited to these examples.

[0057] Example 1. 하원 성성적 다하스 T 리프구 아이스

[0058] Antigen-specific pluripotent T lymphocytes were analyzed according to the schematic method shown in Figure 1. Human peripheral blood mononuclear cells (huPBMCs) were collected from healthy donors who had previously been exposed to the SARS-CoV2 virus and cryopreserved in liquid nitrogen. Subsequently, the liquid nitrogen was removed from the cryopreserved samples, and they were rapidly thawed in a water bath at 37°C. The samples were then washed with RPMI and incubated at room temperature for 20 minutes in RPMI / 10% FBS medium supplemented with 1 X DNase (Sigma Aldrich) and penicillin / streptomycin (Thermo Fisher Scientific). Cultured cells were treated for 6 hours in the presence of the protein transport inhibitor golgiplug with PMA / ionomycin (positive control, Sigma Aldrich, #P1585, #I9657), Pan-SARS-CoV2 peptide mixture (PM-Pan-SARS2select01-1, JPT), SARS-CoV2 BA1.1 / Omicron peptide mixture (PM-SARS2-SMUT08-1, JPT), or SARS-CoV2 Omicron variant (PepTivator ®The cells were stimulated with SARS-CoV2 Prot_S B.1.1.529 / BA.2 WT Reference Pool (Mitenyi). The variant information of the above SARS-CoV2 omicron variant relative to the SARS-CoV2 spike Wuhan wild type is shown in Table 1 below. Subsequently, cells stimulated with each antigen were washed with 1% BSA (Thermo Fisher Scientific) and PBS (Gibco, Thermo Fisher Scientific) that did not contain calcium or magnesium. Then, to stain the antigens on the cell surface, the cells were stained with 50 μL of PBS containing an antibody mixture (Standard Biotools, Maxpar® Human T-Cell Phenotyping Panel Kit, 16 Marker-25 Tests, Product Number 201305) and 1% BSA. The stained cells were washed with PBS and 1% BSA and then fixed with 1.6% paraformaldehyde (Electron Microscopy Sciences).

[0059] SARS-COV-2 spike protein Wuhan wild type Mutations in the B.1.1.529 lineage Sequence position Amino acids BA.1 BA.2 19 T19 - T19I 24 L24 - L24deletion 25 P25 - P25deletion 26 P26 - P26deletion 27 A27 - A27S 67 A67 A67V - 69 H69 H69deletion 70 V70 V70deletion - 95 T95 T95I - 142 G142 G142D G142D 143 V143 V143deletion - 144 Y144 Y144deletion - 145 Y145 Y145deletion - 211 N211 N211deletion - 212 L212 L212I - 213 V213 - V213G 214 - Insertion214EPE - 339 G339 G339D G339D 371 S371 S371L S371L 373 S373 S373P S373P 375 S375 S375F S375F 376 T376 - T376A 405 D405 - D405N 408 R408 - R408S 417 K417 K417N K417N 440 N440 N440K N440K 446 G446 G446S - 477 S477 S477N S477N 478 T478 T478K T478K 484 E484 E484A E484A 493 Q493 Q493R Q493R 496 G496 G496S - 498 Q498 Q498R Q498R 501 N501 N501Y N501Y 505 Y505 Y505H Y505H 547 T547 T547K - 614 D614 D614G D614G 655 H655 H655Y H655Y 679 N679 N679K N679K 681 P681 P681H P681H 764 N764 N764K N764K 796 D796 D796Y D796Y 856 N856 N856K - 954 Q954 Q954H Q954H 969 N969 N969K N969K 981 L981 L981F -

[0060] Subsequently, the cells were washed once with PBS and resuspended in cold methanol (ThermoFisher Scientific) to increase cell permeability and permeate the cells. After incubating the permeated cells overnight at -20°C, they were stained with 50 μL of PBS containing the antibody cocktail and 1% BSA to stain intracellular antigens. Subsequently, the cells were washed with PBS and 1% BSA, washed once more with PBS, and stained with an iridium DNA intercalator (Standard BioTools) in 1.6% paraformaldehyde at room temperature for 20 minutes. Afterward, the cells were washed with PBS and diH2O, resuspended in 1X EQ Four Element Calibration Beads (Fluidigm), and collected in a Helios mass cytometer (Standard BioTools), a type of CyTOF. Further analysis and data visualization were performed using Cytobank.

[0061] As a result, as shown in Figure 2, when stimulated with PMA / ionomycin (positive control), IL-2, IFNγ, TNFα, and MIP1b were strongly produced, whereas when stimulated with SARS-CoV2 peptides, IFNγ, TNFα, and MIP1b were produced as observed in a single cluster. In other words, it was confirmed that SARS-CoV2-specific T lymphocytes belong to a late memory T lymphocyte subgroup that produces IFNγ, TNFα, and MIP1b. Furthermore, through this, it was confirmed that the functional activation of antigen-specific T lymphocytes can be evaluated using CyTOF.

[0063] From the foregoing description, those skilled in the art to which the present invention pertains will understand that the present invention may be implemented in other specific forms without altering its technical concept or essential features. In this regard, the embodiments described above should be understood as illustrative in all respects and not restrictive. The scope of the present invention should be interpreted as including all modifications or variations derived from the meaning and scope of the claims set forth below and their equivalents, rather than from the detailed description above.

Claims

Claim 1 A method for measuring a cellular immune response to a specific antigen using T lymphocytes, comprising the step of detecting antigen-specific pluripotent T lymphocytes in a sample stimulated by an antigen, wherein the antigen-specific pluripotent T lymphocytes secrete IFNγ, TNFα, and MIP1b, and the antigen is a coronavirus, wherein the method confirms whether immunity to the antigen is acquired by detecting antigen-specific pluripotent T lymphocytes in a sample, and wherein the step of detecting antigen-specific pluripotent T lymphocytes is measured using a mass cytometer. Claim 2 A method for measuring a cellular immune response to a specific antigen using T lymphocytes, wherein, in claim 1, a sample stimulated by an antigen is obtained by contacting an isolated sample with an antigen-derived peptide and culturing it. Claim 3 delete Claim 4 delete Claim 5 A method for measuring a cellular immune response to a specific antigen using T lymphocytes, wherein the sample is blood or peripheral blood mononuclear cells separated from blood, in accordance with claim 1. Claim 6 delete Claim 7 delete Claim 8 delete Claim 9 A method for providing information for determining whether acquired immunity to a specific antigen has been acquired, comprising the step of detecting antigen-specific pluripotent T lymphocytes in a sample stimulated by an antigen, wherein the antigen-specific pluripotent T lymphocytes secrete IFNγ, TNFα, and MIP1b, and the antigen is a coronavirus, and the method determines whether immunity to the antigen has been acquired by detecting antigen-specific pluripotent T lymphocytes in a sample, and the step of detecting antigen-specific pluripotent T lymphocytes is measured by a mass cytometer. Claim 10 A method for providing information for confirming whether acquired immunity to a specific antigen has been acquired, wherein, in claim 9, a sample stimulated by an antigen is obtained by contacting and culturing an antigen-derived peptide with a separated sample. Claim 11 delete Claim 12 delete Claim 13 A method for providing information for confirming whether acquired immunity to a specific antigen has been acquired, wherein, in claim 9, the sample is blood or peripheral blood mononuclear cells separated from blood. Claim 14 delete Claim 15 delete Claim 16 delete

Citation Information

Patent Citations

  • Methods for diagnosis of immune responses against viruses

    KR1020120117008A

  • Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy

    KR1020170068600A

  • Anti-tigit antigen-binding proteins and methods of use thereof

    KR1020180068990A

  • Methods of immunotherapy

    KR1020190028662A

  • Multiple antigen presenting immunogenic composition, and methods and uses thereof

    KR1020190104631A